Skip to content

Mechanistic Studies of Chronic COPD Using Single-Cell Sequencing and Single-Cell Spatial Transcriptomics

A Bidirectional Cohort Study of Single-Cell Sequencing and Single-Cell Spatial Transcriptomics in Chronic COPD

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07208123
Enrollment
150
Registered
2025-10-06
Start date
2025-09-30
Completion date
2027-12-31
Last updated
2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD

Brief summary

This study is an ambispective cohort study, the sample from patients were from both previously stored and freshly collected . The objective of this study is to investigate the molecular pathological changes underlying the development of chronic obstructive pulmonary disease (COPD). We will use single cell sequencing technology to analyze lung tissue samples from patients who underwent lung resection, with lung tissue from patients without COPD serving as controls. This research aims to provide insights into the pathogenesis of COPD.

Interventions

None listed

Sponsors

Tongji University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
OTHER

Eligibility

Sex/Gender
ALL

Inclusion criteria

* Receiving lung resection surgery at the hospital for any reason; * Diagnosed with COPD according to the 2024 GOLD guidelines; * Tissue samples that meet collection requirements and are either agreed to be collected or already preserved;

Exclusion criteria

* Improper preservation of pathological specimens, refusal to consent to sample collection, or incomplete clinical information; * Combined with other factors causing obstructive airflow limitation; * Diagnosed with asthma according to the GINA 2023 guidelines and with a history of asthma exacerbations within the past year; * Combined with Advanced lung cancer; * Receiving systemic immunosuppressive medications such as anti-rejection drugs;

Design outcomes

Primary

MeasureTime frame
Transcriptomic profile analysis of lung tissuesuntil end of surgery

Countries

China

Contacts

Primary ContactFeng Xinyu, Dr
52290946015@stu.ecnu.edu.cn86-17621694653

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026